Skip to contentW
Windtree Therapeutics Inc
W
WINTWindtree Therapeutics Inc Q2 2016 · 10-Q
Revenue$106.00K$106.00K+41.3% vs Q2 2015 Net Income-$10.62M-$10.62MN/M vs Q2 2015 EPS Diluted-$1.29-$1.29N/M vs Q2 2015 Operating Income-$9,993,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Windtree Therapeutics Inc · CIK 946486 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$9,139,000N/M Margins · derivedOperating margin-9427.4%+4488.6 pt vs Q2 2015
Net margin-10022.6%+5078.7 pt vs Q2 2015
ended Jun 30, 2016 · filed Aug 10, 2016 · 41 d after period end